RhumbLine Advisers’s Cantel Medical Corporation CMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-109,706
| Closed | -$8.76M | – | 3192 |
|
|
2021
Q1 | $8.76M | Sell |
109,706
-3,197
| -3% | -$250K | 0.01% | 1075 |
|
|
2020
Q4 | $8.9M | Buy |
112,903
+3,851
| +4% | +$226K | 0.01% | 1000 |
|
|
2020
Q3 | $4.79M | Sell |
109,052
-12,046
| -10% | -$593K | 0.01% | 1198 |
|
|
2020
Q2 | $5.36M | Buy |
121,098
+15,911
| +15% | +$594K | 0.01% | 1172 |
|
|
2020
Q1 | $3.78M | Buy |
105,187
+3,560
| +4% | +$202K | 0.01% | 1199 |
|
|
2019
Q4 | $7.21M | Buy |
101,627
+1,634
| +2% | +$119K | 0.01% | 1040 |
|
|
2019
Q3 | $7.48M | Sell |
99,993
-712
| -0.7% | -$60.4K | 0.01% | 947 |
|
|
2019
Q2 | $8.12M | Sell |
100,705
-2,033
| -2% | -$143K | 0.02% | 904 |
|
|
2019
Q1 | $6.87M | Buy |
102,738
+1,126
| +1% | +$85.3K | 0.01% | 987 |
|
|
2018
Q4 | $7.57M | Buy |
101,612
+21,175
| +26% | +$1.75M | 0.02% | 860 |
|
|
2018
Q3 | $7.41M | Sell |
80,437
-595
| -0.7% | -$56.7K | 0.01% | 856 |
|
|
2018
Q2 | $7.97M | Buy |
81,032
+5,724
| +8% | +$640K | 0.02% | 794 |
|
|
2018
Q1 | $8.39M | Sell |
75,308
-12,540
| -14% | -$1.41M | 0.02% | 742 |
|
|
2017
Q4 | $9.04M | Buy |
87,848
+11,352
| +15% | +$1.13M | 0.02% | 729 |
|
|
2017
Q3 | $7.2M | Buy |
76,496
+870
| +1% | +$68.7K | 0.02% | 833 |
|
|
2017
Q2 | $5.89M | Sell |
75,626
-497
| -0.7% | -$37.3K | 0.01% | 908 |
|
|
2017
Q1 | $6.1M | Buy |
76,123
+5,949
| +8% | +$473K | 0.01% | 888 |
|
|
2016
Q4 | $5.53M | Buy |
70,174
+3,204
| +5% | +$249K | 0.01% | 883 |
|
|
2016
Q3 | $5.22M | Buy |
66,970
+3,491
| +5% | +$253K | 0.01% | 857 |
|
|
2016
Q2 | $4.36M | Buy |
63,479
+1,561
| +3% | +$108K | 0.01% | 885 |
|
|
2016
Q1 | $4.42M | Buy |
61,918
+1,030
| +2% | +$64.7K | 0.01% | 901 |
|
|
2015
Q4 | $3.78M | Buy |
60,888
+4,080
| +7% | +$249K | 0.01% | 958 |
|
|
2015
Q3 | $3.22M | Sell |
56,808
-3,144
| -5% | -$166K | 0.01% | 1050 |
|
|
2015
Q2 | $3.22M | Sell |
59,952
-2,675
| -4% | -$130K | 0.01% | 1103 |
|
|
2015
Q1 | $2.98M | Buy |
62,627
+23,967
| +62% | +$1.06M | 0.01% | 1134 |
|
|
2014
Q4 | $1.67M | Sell |
38,660
-525
| -1% | -$21.4K | ﹤0.01% | 1480 |
|
|
2014
Q3 | $1.35M | Buy |
39,185
+715
| +2% | +$25.3K | ﹤0.01% | 1568 |
|
|
2014
Q2 | $1.41M | Sell |
38,470
-1,226
| -3% | -$41.6K | ﹤0.01% | 1604 |
|
|
2014
Q1 | $1.34M | Sell |
39,696
-1,527
| -4% | -$50.4K | ﹤0.01% | 1612 |
|
|
2013
Q4 | $1.4M | Sell |
41,223
-280
| -0.7% | -$9.7K | ﹤0.01% | 1586 |
|
|
2013
Q3 | $1.32M | Sell |
41,503
-1,856
| -4% | -$49.4K | ﹤0.01% | 1597 |
|
|
2013
Q2 | $979K | Buy |
+43,359
| New | +$939K | ﹤0.01% | 1783 |
|
RhumbLine Advisers's CMD Position: Q2 2021 in Review
RhumbLine Advisers sold out of Cantel Medical Corporation (CMD) in Q2 2021, closing a stake of 109,706 shares — an estimated $8.76M sold.
RhumbLine Advisers first reported a position in CMD in Q2 2013 and held it in 32 quarters. The position peaked at $9.04M in Q4 2017. 0 funds tracked by Wall St. Rank hold CMD as of Q2 2021.
- RhumbLine Advisers reported no remaining Cantel Medical Corporation position as of Q2 2021 after selling out during the quarter.
- RhumbLine Advisers sold 109,706 Cantel Medical Corporation shares in Q2 2021, an estimated $8.76M.
- RhumbLine Advisers first reported a position in Cantel Medical Corporation in Q2 2013 and held it in 32 quarters.
- RhumbLine Advisers's Cantel Medical Corporation position peaked at $9.04M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q2 2021.
Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.